Subject    :    [2017 Feb;41(1)] Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus
Writer KDA
Date 2017-03-23 10:32:13 Hit 7,625
Diabetes Metab J. 2017 Feb;41(1):23-30. English. Published online Dec 16, 2016.  https://doi.org/10.4093/dmj.2017.41.1.23 
Copyright © 2017 Korean Diabetes Association
   
Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus
Sung Hye Kong,1 Bo Kyung Koo,1,2 and Min Kyong Moon1,2
1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
2Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
Corresponding author: Min Kyong Moon. Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, 20 Boramae-ro 5-gil, Dongjak-gu, Seoul 07061, Korea. Email: mkmoon@snu.ac.kr 
 
Received April 14, 2016; Accepted August 02, 2016.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract
Background

There has been evidences of ethnic differences in the low density lipoprotein cholesterol (LDL-C) lowering effect of statin. We aimed to evaluate the efficacy of moderate-intensity statins in the treatment of dyslipidemia among Korean patients with type 2 diabetes mellitus (T2DM).

Methods

We analyzed a retrospective cohort that consisted of Korean patients with T2DM aged 40 to 75 years who had been prescribed any of the moderate-intensity statins (atorvastatin 10 or 20 mg, rosuvastatin 5 or 10 mg, pitavastatin 2 mg, or pravastatin 40 mg). Among them, only patients with baseline lipid profiles before starting statin treatment were selected, and changes in their lipid profiles before and 6 months after statin therapy were analyzed.

Results

Following the first 6 months of therapy, the overall LDL-C reduction was −47.4% (interquartile range, −56.6% to −34.1%). In total, 92.1% of the participants achieved an LDL-C level of

Conclusion

In conclusion, the use of moderate-intensity statins reduced LDL-C levels less than 100 mg/dL in most of the Korean patients studied with T2DM. The efficacies of those statins were higher than expected in about 42% of Korean patients with T2DM.

   
Keywords:
Diabetes mellitus, type 2; Dyslipidemia; Efficacy; Statin
 

Articles - Reviews in DMJ
No. Subject Date Hit ↓
283 [2019 Feb;43(1)] Higher High Density Lipoprotein 2 (HDL2) to Total H... 2019-03-06 15
282 [2019 Feb;43(1)] Proportion and Characteristics of the Subjects with... 2019-03-06 13
281 [2019 Feb;43(1)] Soluble Dipeptidyl Peptidase-4 Levels Are Associate... 2019-03-06 15
280 [2019 Feb;43(1)] Projection of Diabetes Prevalence in Korean Adults ... 2019-03-06 26
279 [2019 Feb;43(1)] High Proportion of Adult Cases and Prevalence of Me... 2019-03-06 10
278 [2019 Feb;43(1)] Association of Bisphenol A and Its Substitutes, Bis... 2019-03-06 10
277 [2019 Feb;43(1)] Hospital-Based Korean Diabetes Prevention Study: A ... 2019-03-06 12
276 [2019 Feb;43(1)] Nonalcoholic Fatty Liver Disease in Diabetes. Part ... 2019-03-06 15
275 [2019 Feb;43(1)] Update on the Impact, Diagnosis and Management of C... 2019-03-06 11
274 [2018 Dec;42(6)] The Prevalence and Risk Factors for Diabetic Retino... 2019-03-06 12

목록

Gets the previous 5 pages.   Go to previous page.  [1]   2   3   4   5     Go to next page. Gets the next  5 pages.